Abacavir 為一種核苷類似物反轉錄酶抑制劑 (nucleoside reverse transcriptase inhibitor)，臨床上併用其他抗病毒藥物用以治療成人及兒童之人類免疫缺乏病毒 (human immunodeficiency viruses) 感染。然而abacavir 可能會引起危及病人生命的過敏反應 (hypersensitivity reactions)，此abacavir 過敏反應 (abacavir hypersensitivity reactions, AHR) 於2002 年即證實與HLA-B*57:01 基因具高度相關性。本文針對 abacavir 與其過敏反應、HLA-B*57:01 基因與AHR 之關聯，以HLA-B*57:01 基因篩檢診斷或預防AHR 之效益進行探討，期望abacavir 在臨床使用上能更加安全而有效。

 

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of human immunodeficiency virus (HIV) infection. It is clinically used in combination with other antiviral medications as part of highly active antiretroviral therapy. Abacavir hypersensitivity reactions (AHR) may be severe and even lifethreatening. In 2002, HLA-B*57:01 genotype was demonstrated to be strongly associated with AHR. We reviewed the association between abacavir, HLA-B*57:01 genotype and AHR to determine the benefits of HLA-B*57:01 genotype screening for

diagnosing or preventing AHR, aiming the clinical management of abacavir safer and more effective in Taiwan.

 

 

Submitted for publication: 2022.5.11 ; Accepted for publication: 2023.10.19